These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36281031)

  • 1. Chemotherapy combined with immunotherapy in primary female urethral squamous cell carcinoma: a case report.
    Bai H; Han H; Wang F; Shi H
    J Int Med Res; 2022 Oct; 50(10):3000605221132418. PubMed ID: 36281031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
    Zhang F; Xu Y; Guo S; Li S; Ma K; Wang J; Wei S
    Ann Palliat Med; 2022 Sep; 11(9):3020-3027. PubMed ID: 36217630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Phase Ⅱ clinical trial of PD-1 inhibitor combined with chemotherapy for locally advanced resectable oral squamous cell carcinoma].
    Wang HL; Yue K; Wu YS; Duan YS; Jing C; Wang XD
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):335-342. PubMed ID: 38599641
    [No Abstract]   [Full Text] [Related]  

  • 4. The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.
    Fujita T; Hiroishi T; Shikano K; Yanagisawa A; Hayama N; Amano H; Nakamura M; Hirano S; Tabeta H; Nakamura S
    Intern Med; 2018 Jul; 57(13):1827-1832. PubMed ID: 29434143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report.
    Zheng Y; Xue YY; Zhao YQ; Chen Y; Li ZP
    Front Immunol; 2023; 14():1254812. PubMed ID: 37901233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment using immunotherapy in combination with chemotherapy for metastatic squamous cell carcinoma of unknown primary origin with bulky abdominal mass: A case report.
    Zhang M; Zhao M; Jin LF; Shen WZ
    Medicine (Baltimore); 2021 Dec; 100(48):e28074. PubMed ID: 35049231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete and enduring response in an elderly patient with repeated recurrent gingival squamous cell carcinoma treated by combined toripalimab and single agent chemotherapy: a case report.
    Wu Q; Zhang S; Hua X; Yu H; Zhong Y
    Ann Palliat Med; 2021 Jun; 10(6):6968-6973. PubMed ID: 33183019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    Zhang Y; Zhou H; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
    Akiyama N; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Uto T; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Suda T
    Invest New Drugs; 2019 Jun; 37(3):531-537. PubMed ID: 30790149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis.
    Xiao W; Yuan Y; Wang S; Liao Z; Cai P; Chen B; Zhang R; Wang F; Zeng Z; Gao Y
    Front Immunol; 2021; 12():798451. PubMed ID: 35095878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
    West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
    Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial.
    Jotte R; Cappuzzo F; Vynnychenko I; Stroyakovskiy D; Rodríguez-Abreu D; Hussein M; Soo R; Conter HJ; Kozuki T; Huang KC; Graupner V; Sun SW; Hoang T; Jessop H; McCleland M; Ballinger M; Sandler A; Socinski MA
    J Thorac Oncol; 2020 Aug; 15(8):1351-1360. PubMed ID: 32302702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A CASE OF UROTHELIAL CARCINOMA OF THE URINARY BLADDER WITH SQUAMOUS DIFFERENTIATION RESPONDING TO PACLITAXEL AND CARBOPLATIN NEOADJUVANT CHEMOTHERAPY].
    Banno E; Nishino A; Nagai Y; Yasuda M; Tahara H; Kino S; Kanno N
    Nihon Hinyokika Gakkai Zasshi; 2015 Jul; 106(3):206-10. PubMed ID: 26419080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial.
    Gridelli C; Chen T; Ko A; O'Brien ME; Ong TJ; Socinski MA; Postmus PE
    Drug Des Devel Ther; 2018; 12():1445-1451. PubMed ID: 29872267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency.
    Yuan S; Hu X; Zhao Y; Wang Z
    Front Immunol; 2020; 11():563622. PubMed ID: 33240259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
    Spigel DR; Jotte RM; Aix SP; Gressot L; Morgensztern D; McCleod M; Socinski MA; Daniel D; Juan-Vidal O; Mileham KF; West H; Page R; Reinmuth N; Knoble J; Chen T; Bhore R; Wolfsteiner M; Ong TJ; Gridelli C; Thomas M;
    Clin Lung Cancer; 2021 Jan; 22(1):6-15.e4. PubMed ID: 33097414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B; Leighl NB; Davies M
    Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma.
    Yuan H; Liu J; Zhang J
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33807509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non-small cell lung cancer.
    Igawa S; Otani S; Nakahara Y; Ryuge S; Hiyoshi Y; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sato Y; Sasaki J; Masuda N
    Invest New Drugs; 2018 Feb; 36(1):45-52. PubMed ID: 28466376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with
    Reck M; Shankar G; Lee A; Coleman S; McCleland M; Papadimitrakopoulou VA; Socinski MA; Sandler A
    Expert Rev Respir Med; 2020 Feb; 14(2):125-136. PubMed ID: 31829747
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.